Key regions: France, India, United Kingdom, South Korea, Japan
The Multiple Sclerosis Drugs market in Tunisia has been experiencing steady growth in recent years, driven by various factors such as customer preferences, local special circumstances, and underlying macroeconomic factors.
Customer preferences: Customers in Tunisia prefer drugs that are effective in treating Multiple Sclerosis (MS) and have minimal side effects. They also prefer drugs that are affordable and easily accessible. As a result, pharmaceutical companies are focusing on developing drugs that meet these preferences.
Trends in the market: One trend in the Multiple Sclerosis Drugs market in Tunisia is the increasing use of generic drugs. This is due to the fact that generic drugs are more affordable than brand-name drugs, making them more accessible to customers. Another trend is the growing demand for disease-modifying therapies, which are drugs that can slow down the progression of MS.
Local special circumstances: Tunisia has a high prevalence of MS, with an estimated 3,000 to 5,000 people living with the disease. This has led to an increase in demand for MS drugs in the country. Additionally, Tunisia has a well-established healthcare system, which has helped to improve access to MS drugs.
Underlying macroeconomic factors: Tunisia has a growing economy, which has led to an increase in healthcare spending. This has enabled the government to invest in the healthcare system, including the provision of MS drugs. Additionally, Tunisia has a favorable regulatory environment for pharmaceutical companies, which has encouraged investment in the country.In conclusion, the Multiple Sclerosis Drugs market in Tunisia is growing due to customer preferences for effective and affordable drugs, the increasing use of generic drugs, the growing demand for disease-modifying therapies, the high prevalence of MS in the country, the well-established healthcare system, the growing economy, and the favorable regulatory environment.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
